Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improves the overall survival of patients with <i>EGFR</i>-mutated non-small-cell lung cancer (NSCLC).
|
30445769 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>Yin-Cold</i> or <i>Yang-Heat</i> Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept.
|
28203260 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Compared with gefitinib alone, gefitinib combined with carboplatin plus pemetrexed improved PFS in patients with untreated advanced NSCLC with EGFR mutations with an acceptable toxicity profile, although its OS benefit requires further validation.
|
31682542 |
2020 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with stage IV EGFR-mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified.
|
29852232 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Medical records of 198 patients with EGFR mutant non-small cell lung cancer and brain metastases at initial metastatic diagnosis were reviewed.
|
31127020 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with NSCLC are therefore tested for EGFR-TK tumour gene mutations to inform treatment decisions.
|
24827857 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We performed a multicentric retrospective analysis on a cohort of consecutive patients treated with osimertinib for an advanced EGFR-mutated NSCLC and collected histo-molecular data from plasma and tumor samples at the time of progression.
|
31600593 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, tailoring treatment according to either histological subtype or EGFR mutation status in advanced NSCLC should today be part of daily practice based on current evidence.
|
21357891 |
2011 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Low activity of poziotinib was detected in patients with <i>EGFR</i>-mutant non-small cell lung cancer who developed AR to gefitinib or erlotinib, potentially because of severe-toxicityimposed dose limitation.
|
27188206 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identification of molecular subsets with differential response to targeted therapies began with the identification of epidermal growth factor receptor mutated tumors in subsets of non-small cell lung cancer (NSCLC).
|
27637426 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we studied the regulation of PD-L1 expression in NSCLC without targetable genetic alterations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET.
|
30972766 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Results of these analyses may have implications for both response (eg, molecular testing for EGFR [epidermal growth factor receptor] mutations) and safety (eg, contraindications for squamous histology) in NSCLC.
|
22424871 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the clinical outcomes of nintedanib and docetaxel in refractory NSCLC according to EGFR mutation status during the Korean nintedanib named patient program.
|
30368503 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively analyzed 2012 non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
|
27062699 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The discovery of activating mutations of epidermal growth factor receptor (EGFR) has resulted in the development of more effective treatments for non-small cell lung cancer (NSCLC).
|
27044261 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The analysis included advanced EGFR-mutated NSCLC patients treated with first-line TKI who experienced RECIST progression between June 2010 and July 2012.
|
26315967 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to compare EGFR mutations between PT and the corresponding MLN in NSCLC patients, and provide some guidelines for clinical treatment using TKI therapy.
|
24969875 |
2014 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR) are responsive to erlotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI).
|
24512728 |
2013 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To date, first-line single agent immune checkpoint blockade has demonstrated limited activity in EGFR mutated NSCLC and the combination of immunotherapy and targeted agents has raised safety concerns in both EGFR and ALK positive NSCLC patients.
|
30954906 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib.
|
27177916 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We also found that treatment with EGFR-TKIs plus chemotherapy was associated with a significantly longer DFS and OS compared to mono chemotherapy in patients with completely resected EGFR-mutant NSCLC (DFS: OR, 0.48; 95% CI, 0.34-0.68; P < 0.0001; heterogeneity I<sup>2</sup> = 47%, P = 0.07; OS: OR, 0.50; 95% CI, 0.31-0.78; P = 0.003; heterogeneity I<sup>2</sup> = 57%, P = 0.05).
|
31421260 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutations were detected in 18 of 48 (42.6%) patients with NSCLC.
|
23886169 |
2013 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to evaluate the influence of EGFR mutation types and subtypes on survival outcomes in advanced Asian patients with NSCLC receiving first-line gefitinib therapy.
|
27908825 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis.
|
21982684 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with EGFR-mutated NSCLC with the BIM deletion, pre-treated with EGFR-TKI and chemotherapy, were recruited.
|
31782583 |
2020 |